Copertina

Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kee Huat Chuah, Qing Yuan Loo, Wen Xuan Hian, Xin Hui Khoo, Sarala Panirsheeluam, Nurhidayah Binti Mohammad Jubri, Vicraman Natarajan, Stanley Khoo, Sanjiv Mahadeva
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
di: Kee Huat Chuah, et al.
Pubblicazione: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
di: Kee Huat Chuah, et al.
Pubblicazione: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
di: Shoko Miyahara, et al.
Pubblicazione: (2025)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
di: Wah Loong Chan, et al.
Pubblicazione: (2024)

Editorial: Proton Pump Inhibitors and the Changing Face of Spontaneous Bacterial Peritonitis
di: S. Quickert, et al.
Pubblicazione: (2026)

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors
di: Philip Kitchen, et al.
Pubblicazione: (2026)

Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30‐Day Mortality From Acute Pancreatitis
di: Maya Fischman, et al.
Pubblicazione: (2025)

Editorial: Heads or Tails in the Treatment of Functional Dyspepsia—Does the Side of the Coin Matter?
di: Cedric Van de Bruaene, et al.
Pubblicazione: (2025)

Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study
di: J. Tack, et al.
Pubblicazione: (2025)

Editorial: New Insights Into the Aetiopathogenesis of Post‐Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next? Authors' Reply
di: Mohamed H. Eldesouki, et al.
Pubblicazione: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
di: Yu Shi, et al.
Pubblicazione: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
di: Shuai Xia, et al.
Pubblicazione: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
di: Jee‐Fu Huang, et al.
Pubblicazione: (2026)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
di: Takao Miwa, et al.
Pubblicazione: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
di: Kelly Torosian, et al.
Pubblicazione: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
di: Romeo Kuo‐Cheng Wu, et al.
Pubblicazione: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
di: Terry Cheuk‐Fung Yip, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
di: Mohammad Saeid Rezaee‐Zavareh, et al.
Pubblicazione: (2026)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
di: Mathilde Osty, et al.
Pubblicazione: (2025)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
di: Nipun Verma, et al.
Pubblicazione: (2024)

Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021
di: Michael H. Le, et al.
Pubblicazione: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance
di: Apichat Kaewdech, et al.
Pubblicazione: (2026)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
di: Stefan Mauss
Pubblicazione: (2025)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
di: Jane Lim, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
di: L. Aceituno, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
di: Cheng‐Hsien Hung, et al.
Pubblicazione: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply
di: Rohit Mehtani, et al.
Pubblicazione: (2026)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
di: Ze‐Hua Zhao, et al.
Pubblicazione: (2025)

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study
di: Saqr Alsakarneh, et al.
Pubblicazione: (2025)

Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP ‐ INDIA Study
di: Nipun Verma, et al.
Pubblicazione: (2026)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
di: Isabella Lurje, et al.
Pubblicazione: (2025)

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study
di: Sara Ellegaard Paaske, et al.
Pubblicazione: (2025)

No value of non‐selective beta‐blockers after TIPS‐insertion
di: Anja Tiede, et al.
Pubblicazione: (2024)